ACB Fundamental Analysis - AURORA CANNABIS INC

Fundamental Rating

ACB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 32 industry peers in the Pharmaceuticals industry. The financial health of ACB is average, but there are quite some concerns on its profitability. ACB is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ACB has reported negative net income.

In the past year ACB had a positive cash flow from operations.

In the past 5 years ACB reported 4 times negative net income.

In the past 5 years ACB reported 4 times negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -7.78%, ACB perfoms like the industry average, outperforming 46.88% of the companies in the same industry.

ACB has a Return On Equity (-11.07%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-7.78%
ROE	-11.07%
ROIC	N/A

ROA(3y)-55.32%

ROA(5y)-62.11%

ROE(3y)-90.28%

ROE(5y)-91.51%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of ACB (1.69%) is worse than 75.00% of its industry peers.

ACB's Gross Margin has declined in the last couple of years.

ACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	1.69%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-29.39%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.

ACB has more shares outstanding than it did 1 year ago.

The number of shares outstanding for ACB has been reduced compared to 5 years ago.

The debt/assets ratio for ACB has been reduced compared to a year ago.

2.2 Solvency

ACB has an Altman-Z score of -10.44. This is a bad value and indicates that ACB is not financially healthy and even has some risk of bankruptcy.

ACB has a Altman-Z score of -10.44. This is amonst the worse of the industry: ACB underperforms 87.50% of its industry peers.

A Debt/Equity ratio of 0.07 indicates that ACB is not too dependend on debt financing.

ACB's Debt to Equity ratio of 0.07 is fine compared to the rest of the industry. ACB outperforms 71.88% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.07
Debt/FCF	N/A
Altman-Z	-10.44

ROIC/WACCN/A

WACC8.18%

2.3 Liquidity

A Current Ratio of 3.41 indicates that ACB has no problem at all paying its short term obligations.

ACB has a better Current ratio (3.41) than 87.50% of its industry peers.

A Quick Ratio of 1.63 indicates that ACB should not have too much problems paying its short term obligations.

With a decent Quick ratio value of 1.63, ACB is doing good in the industry, outperforming 68.75% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.41
Quick Ratio	1.63

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ACB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.85%, which is quite impressive.

ACB shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.87%.

Measured over the past years, ACB shows a small growth in Revenue. The Revenue has been growing by 6.94% on average per year.

EPS 1Y (TTM)57.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-4.55%

Revenue 1Y (TTM)23.87%

Revenue growth 3Y11.86%

Revenue growth 5Y6.94%

Sales Q2Q%11.4%

3.2 Future

ACB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.58% yearly.

ACB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.91% yearly.

EPS Next Y-288.53%

EPS Next 2Y206.48%

EPS Next 3Y81.3%

EPS Next 5Y103.58%

Revenue Next Year8.72%

Revenue Next 2Y7.21%

Revenue Next 3Y7.75%

Revenue Next 5Y7.91%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACB. In the last year negative earnings were reported.

The Price/Forward Earnings ratio is 13.61, which indicates a correct valuation of ACB.

81.25% of the companies in the same industry are more expensive than ACB, based on the Price/Forward Earnings ratio.

When comparing the Price/Forward Earnings ratio of ACB to the average of the S&P500 Index (36.59), we can say ACB is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	13.61

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ACB's earnings are expected to grow with 81.30% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y206.48%

EPS Next 3Y81.3%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ACB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AURORA CANNABIS INC

TSX:ACB (11/27/2025, 7:00:00 PM)

6.39

-0.04 (-0.62%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-05 2025-11-05/bmo

Earnings (Next)02-03 2026-02-03/bmo

Inst Owners15.09%

Inst Owner ChangeN/A

Ins Owners0.03%

Ins Owner ChangeN/A

Market Cap362.31M

Revenue(TTM)367.13M

Net Income(TTM)-58.89M

Analysts73.33

Price Target8.08 (26.45%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-402.09%

Min EPS beat(2)-587.94%

Max EPS beat(2)-216.23%

EPS beat(4)1

Avg EPS beat(4)815.79%

Min EPS beat(4)-587.94%

Max EPS beat(4)4494.06%

EPS beat(8)2

Avg EPS beat(8)364.08%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)0.81%

Min Revenue beat(2)-0.84%

Max Revenue beat(2)2.46%

Revenue beat(4)3

Avg Revenue beat(4)4.08%

Min Revenue beat(4)-0.84%

Max Revenue beat(4)13.79%

Revenue beat(8)6

Avg Revenue beat(8)4.16%

Revenue beat(12)8

Avg Revenue beat(12)3.93%

Revenue beat(16)9

Avg Revenue beat(16)2.81%

PT rev (1m)0%

PT rev (3m)-5.93%

EPS NQ rev (1m)15.91%

EPS NQ rev (3m)5.16%

EPS NY rev (1m)0%

EPS NY rev (3m)-127.78%

Revenue NQ rev (1m)-0.27%

Revenue NQ rev (3m)-1.75%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-1.54%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	13.61
P/S	0.99
P/FCF	N/A
P/OCF	161.53
P/B	0.68
P/tB	0.77
EV/EBITDA	N/A

EPS(TTM)-0.36

EYN/A

EPS(NY)0.47

Fwd EY7.35%

FCF(TTM)-0.32

FCFYN/A

OCF(TTM)0.04

OCFY0.62%

SpS6.47

BVpS9.38

TBVpS8.31

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-7.78%
ROE	-11.07%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	1.69%
FCFM	N/A

ROA(3y)-55.32%

ROA(5y)-62.11%

ROE(3y)-90.28%

ROE(5y)-91.51%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-29.39%

F-Score5

Asset Turnover0.49

Health

		Industry Rank	Sector Rank
Debt/Equity	0.07
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	86.37%
Cap/Sales	5.6%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.41
Quick Ratio	1.63
Altman-Z	-10.44

F-Score5

WACC8.18%

ROIC/WACCN/A

Cap/Depr(3y)56.47%

Cap/Depr(5y)106.5%

Cap/Sales(3y)8.76%

Cap/Sales(5y)35.04%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)57.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-4.55%

EPS Next Y-288.53%

EPS Next 2Y206.48%

EPS Next 3Y81.3%

EPS Next 5Y103.58%

Revenue 1Y (TTM)23.87%

Revenue growth 3Y11.86%

Revenue growth 5Y6.94%

Sales Q2Q%11.4%

Revenue Next Year8.72%

Revenue Next 2Y7.21%

Revenue Next 3Y7.75%

Revenue Next 5Y7.91%

EBIT growth 1Y-6.76%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year95.45%

EBIT Next 3Y30.87%

EBIT Next 5Y26.54%

FCF growth 1Y87.09%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y101.77%

OCF growth 3YN/A

OCF growth 5YN/A

AURORA CANNABIS INC / ACB.CA FAQ

Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ACB.CA.

Can you provide the valuation status for AURORA CANNABIS INC?

ChartMill assigns a valuation rating of 3 / 10 to AURORA CANNABIS INC (ACB.CA). This can be considered as Overvalued.

What is the profitability of ACB stock?

AURORA CANNABIS INC (ACB.CA) has a profitability rating of 1 / 10.

AURORA CANNABIS INC (ACB.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

AURORA CANNABIS INC / ACB.CA FAQ

Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?

Can you provide the valuation status for AURORA CANNABIS INC?

What is the profitability of ACB stock?